90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT

Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. doi: 10.1007/s00259-004-1752-1. Epub 2005 Mar 17.

Abstract

Purpose: The intra-arterial administration of 90Y microspheres is a new palliative treatment option for unresectable liver metastases. The aim of this study was to quantitatively assess changes in FDG uptake and tumour size following 90Y microsphere treatment (SIR-Spheres) using 18F-fluorodeoxyglucose (FDG) PET/CT imaging.

Methods: Five patients with unresectable liver metastases who had failed multiple prior chemotherapy regimens received seven 90Y microsphere treatments to a single liver lobe. All patients underwent a baseline PET/CT scan prior to treatment, as well as up to four follow-up PET/CT scans. The tumour area of 30 liver metastases was measured on CT and the FDG uptake was semiquantitatively assessed by calculation of standardised uptake values (SUVs). A total of 18 FDG-PET/CT scans were performed.

Results: The SUVs in the 30 treated liver metastases decreased from 6.5+/-2.3 at baseline to 4.2+/-1.8 after the first follow-up PET/CT scan (p=0.001). In contrast, the SUVs of untreated metastases increased slightly from 7.2+/-2.3 to 8.0+/-0.8. There was no difference in FDG uptake in treated versus untreated normal liver tissue. Using a previously defined threshold of 20% decrease in SUV from baseline to determine response, 20 out of 30 liver metastases were considered to have responded at the first follow-up PET/CT scan approximately 1 month after treatment. In these metastases, the SUV decreased by 47+/-12%, compared with a slight increase by 5.9+/-19% in ten non-responding metastases (p=0.0001). The changes in tumour size did not correlate with changes in FDG uptake. On the first follow-up PET/CT scan, the tumour area on CT increased by 3.1+/-57% in treated metastases compared with 23.3+/-32% in untreated metastases. A wide range of post-treatment changes of target lesions was observed on CT, including an increase in the size of hypodense lesions, necrotic features and complete resolution of CT abnormalities.

Conclusion: The metabolic information obtained from FDG-PET/CT seems to provide a more accurate and earlier assessment of therapy response following 90Y microsphere treatment than does the anatomical CT information.

MeSH terms

  • Adult
  • Aged
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Humans
  • Liver / pathology
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / secondary
  • Male
  • Microspheres
  • Middle Aged
  • Neoplasm Metastasis
  • Pancreatic Neoplasms / pathology*
  • Positron-Emission Tomography / methods*
  • Retrospective Studies
  • Time Factors
  • Tomography, X-Ray Computed / methods*
  • Treatment Outcome
  • Yttrium Radioisotopes*

Substances

  • Yttrium Radioisotopes
  • Fluorodeoxyglucose F18